Literature DB >> 22492860

Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations.

Anjali N Kunz1, Afrin A Begum, Hong Wu, Jonathan A D'Ambrozio, James M Robinson, William M Shafer, Margaret C Bash, Ann E Jerse.   

Abstract

BACKGROUND: Quinolone-resistant Neisseria gonorrhoeae (QRNG) arise from mutations in gyrA (intermediate resistance) or gyrA and parC (resistance). Here we tested the consequence of commonly isolated gyrA(91/95) and parC86 mutations on gonococcal fitness.
METHODS: Mutant gyrA(91/95) and parC86 alleles were introduced into wild-type gonococci or an isogenic mutant that is resistant to macrolides due to an mtrR(-79) mutation. Wild-type and mutant bacteria were compared for growth in vitro and in competitive murine infection.
RESULTS: In vitro growth was reduced with increasing numbers of mutations. Interestingly, the gyrA(91/95) mutation conferred an in vivo fitness benefit to wild-type and mtrR(-79) mutant gonococci. The gyrA(91/95), parC86 mutant, in contrast, showed a slight fitness defect in vivo, and the gyrA(91/95), parC86, mtrR(-79) mutant was markedly less fit relative to the parent strains. A ciprofloxacin-resistant (Cip(R)) mutant was selected during infection with the gyrA(91/95), parC86, mtrR(-79) mutant in which the mtrR(-79) mutation was repaired and the gyrA(91) mutation was altered. This in vivo-selected mutant grew as well as the wild-type strain in vitro.
CONCLUSIONS: gyrA(91/95) mutations may contribute to the spread of QRNG. Further acquisition of a parC86 mutation abrogates this fitness advantage; however, compensatory mutations can occur that restore in vivo fitness and maintain Cip(R).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22492860      PMCID: PMC3415892          DOI: 10.1093/infdis/jis277

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  45 in total

1.  Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori.

Authors:  B Björkholm; M Sjölund; P G Falk; O G Berg; L Engstrand; D I Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  Daniel E Rozen; Lesley McGee; Bruce R Levin; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  Alpha-2,3-sialyltransferase enhances Neisseria gonorrhoeae survival during experimental murine genital tract infection.

Authors:  Hong Wu; Ann E Jerse
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family.

Authors:  W M Shafer; X Qu; A J Waring; R I Lehrer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

5.  Use of a non-selective transformation technique to construct a multiply restriction/modification-deficient mutant of Neisseria gonorrhoeae.

Authors:  J S Gunn; D C Stein
Journal:  Mol Gen Genet       Date:  1996-07-19

Review 6.  Fitness of antimicrobial-resistant Campylobacter and Salmonella.

Authors:  Qijing Zhang; Orhan Sahin; Patrick F McDermott; Sophie Payot
Journal:  Microbes Infect       Date:  2006-03-31       Impact factor: 2.700

7.  Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones.

Authors:  J Ruiz; A Jurado; E Garcia-Méndez; F Marco; L Aguilar; M T Jiménez de Anta; J Vila
Journal:  J Antimicrob Chemother       Date:  2001-10       Impact factor: 5.790

8.  Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness.

Authors:  Douglas M Warner; William M Shafer; Ann E Jerse
Journal:  Mol Microbiol       Date:  2008-08-27       Impact factor: 3.501

9.  Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies.

Authors:  A A Vickers; A J O'Neill; I Chopra
Journal:  J Antimicrob Chemother       Date:  2007-06-07       Impact factor: 5.790

10.  High occurrence of simultaneous mutations in target enzymes and MtrRCDE efflux system in quinolone-resistant Neisseria gonorrhoeae.

Authors:  Beti Ernawati Dewi; Sasaki Akira; Hideo Hayashi; William Ba-Thein
Journal:  Sex Transm Dis       Date:  2004-06       Impact factor: 2.830

View more
  38 in total

1.  Effects of Formulation on Microbicide Potency and Mitigation of the Development of Bacterial Insusceptibility.

Authors:  Nicola L Cowley; Sarah Forbes; Alejandro Amézquita; Peter McClure; Gavin J Humphreys; Andrew J McBain
Journal:  Appl Environ Microbiol       Date:  2015-08-07       Impact factor: 4.792

2.  High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  Brandon Eilertson; Fernanda Maruri; Amondrea Blackman; Miguel Herrera; David C Samuels; Timothy R Sterling
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

3.  Alanine 501 Mutations in Penicillin-Binding Protein 2 from Neisseria gonorrhoeae: Structure, Mechanism, and Effects on Cephalosporin Resistance and Biological Fitness.

Authors:  Joshua Tomberg; Alena Fedarovich; Leah R Vincent; Ann E Jerse; Magnus Unemo; Christopher Davies; Robert A Nicholas
Journal:  Biochemistry       Date:  2017-02-16       Impact factor: 3.162

Review 4.  Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future.

Authors:  Magnus Unemo; William M Shafer
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

Review 5.  Origin and proliferation of multiple-drug resistance in bacterial pathogens.

Authors:  Hsiao-Han Chang; Ted Cohen; Yonatan H Grad; William P Hanage; Thomas F O'Brien; Marc Lipsitch
Journal:  Microbiol Mol Biol Rev       Date:  2015-03       Impact factor: 11.056

6.  Cryptic Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance.

Authors:  John Z Metcalfe; Elizabeth Streicher; Grant Theron; Rebecca E Colman; Christopher Allender; Darrin Lemmer; Rob Warren; David M Engelthaler
Journal:  Am J Respir Crit Care Med       Date:  2017-11-01       Impact factor: 21.405

7.  Altered Competitive Fitness, Antimicrobial Susceptibility, and Cellular Morphology in a Triclosan-Induced Small-Colony Variant of Staphylococcus aureus.

Authors:  Sarah Forbes; Joe Latimer; Abdulrahman Bazaid; Andrew J McBain
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

8.  Cephalosporin resistance in Neisseria gonorrhoeae infections--reply.

Authors:  Robert D Kirkcaldy; Gail A Bolan; Judith N Wasserheit
Journal:  JAMA       Date:  2013-05-15       Impact factor: 56.272

9.  Impact of an Antimicrobial Stewardship Intervention on Within- and Between-Patient Daptomycin Resistance Evolution in Vancomycin-Resistant Enterococcus faecium.

Authors:  Clare L Kinnear; Twisha S Patel; Carol L Young; Vincent Marshall; Duane W Newton; Andrew F Read; Robert J Woods
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

10.  Identification of amino acids conferring high-level resistance to expanded-spectrum cephalosporins in the penA gene from Neisseria gonorrhoeae strain H041.

Authors:  Joshua Tomberg; Magnus Unemo; Makoto Ohnishi; Christopher Davies; Robert A Nicholas
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.